HNSCC Treatment Advancements: Findings from ESMO Congress 2024

14 Oct 2024Oncology

Adiya Ualiyeva

This content is sponsored. It is intended for healthcare professionals only.

Head and neck cancer remains a significant clinical challenge, with approximately 1,500 new cases annually in Hong Kong, according to the Hospital Authority.1 The ESMO Congress 2024 presented pivotal studies on advances in treatments for head and neck squamous cell carcinoma (HNSCC) that demonstrated enhanced efficacy and manageable safety profiles.

HNSCC Treatment Advancements: Findings from ESMO Congress 2024

For healthcare professionals

This sponsored content is for registered Hong Kong doctors. Log in or register to read it. If you received an access link, open it from your email.